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Introduction
•

•

•

•

•

•

A mean pulmonary artery pressure
greater than 25 mm Hg is defined as
pulmonary hypertension (PH) while
“chronic thromboembolic pulmonary
hypertension (CTEPH) is defined as
pulmonary hypertension in the
presence of an organized thrombus
within the pulmonary vascular bed
that persists at least 3 months after
the onset of anticoagulant therapy”
(Gopalan et al., 2016, p. 222).
CTEPH is “classified within Group 4
PH, which is characterized
pathologically by organized
thromboembolic material and by
altered vascular remodeling initiated
or potentiated by a combination of
defective angiogenesis, impaired
fibrinolysis and endothelial
dysfunction” (Sumimoto et al., 2020,
p. 1053
While necessary, it is not enough to
have persistent perfusion defect to
develop CTEPH “Approximately 30%
of patients have persistent defects
after 6 months of anticoagulation,
but only 10% of those with
persistent defects subsequently
develop CTEPH” (Fernandes et al.,
2016, p. 207).

A Rare and Underdiagnosed Form of
Pulmonary Hypertension

Clinical Presentation
Signs and Symptoms
•
•
•

•
•

Signs and symptoms are minimal early
in the course of the disease
Exertional dyspnea and unexplained
exercise intolerance
Atypical chest pain, nonproductive
cough and episodic hemoptysis are
observed less frequently
More progressive CTEPH will present
similar to right ventricular heart failure.
Symptoms would include:
o
Tricuspid regurgitant murmur
o
S4 cardiac gallop and a right
ventricular S3
o
Pronounced pulmonic component
of the second heart sound
o
Peripheral edema
o
Hepatic congestion and pulsatility
and ascites
o
Jugular Venous distention
o
Cyanosis (Gopalan et al., 2016)
o
Patients re at a higher risk for
developing right ventricular
dysfunction and death (Sumimoto
et al., 2020)

Risk Factors

Diagnosis

Underlying and Significance of
Pathophysiology
•
•

•
•

•

Figure 2: A diagnostic algorithm
developed by UCSD Health, the
leading medical center in advancing
the treatment of CTEPH patients
(Mahmud et al., 2018).

•

In almost 25% of CTEPH patients there was no prior documented history of
acute PE and 44% did not have a prior history of a deep venous thrombosis
(DVT) (Gopalan et al., 2016).
There are still many uncertainties surrounding the pathophysiology and
epidemiology of CTEPH. Questions remain concerning what how genetics
and environmental exposures contribute to the development of the
disease process (Auger et al.).
CTEPH is a form of pre-capillary pulmonary hypertension.
The unresolved PE transforms into chronic, fibrotic, flow-limiting thrombus
in the presence of persistent perfusion defects. These vascular scars
compromise the pulmonary arterial bed leading to pulmonary
hypertension (Fernandes et al., 2016).
CTEPH is a dual vascular disorder with stenosis webs, and occlusions found
primarily at the sites of previous PE in the large and medium pulmonary
arteries. In the low-resistance vessels a secondary vasculopathy resembling
other forms of PH is found. Through the progression of the disease,
anastomosis of bronchial artery branches and precapillary pulmonary
arterioles occurs. Venous remodeling arise is areas where vascular
connections between bronchial arteries and pulmonary veins are formed
(Lang et al. 2016).
Sustained PH will cause unsustainable strain on the right ventricle (RV)
leading to cor pulmonale. The elevated pulmonary artery pressures
increase the workload of the RV, causing hypertrophy. Hypertrophy
obstructs coronary perfusion leading to ischemia, decreased contractility,
and increased RV overload (Mccance & Huether, 2019).

Roughly 0.4 to 9.1% of patients who
have acute pulmonary emboli (PE)
develop CTEPH and “long-term
prognosis is associated with
significant mortality. Patients with
CTEPH experience debilitating
symptoms that have a negative
impact on their quality of life in
terms of physical capability,
psychological wellbeing, and social
relationships” (Kamenskaya et al.,
2017, p. 747)
“Because PH is uncommon and there
is limited awareness, most patients
receive the diagnosis late in the
disease course, which results in
delayed initiation of effective
therapies, greater patient suffering
and potentially worse long-term
clinical outcomes, including survival”
(Hambly et al., 2016, p. 804).
Because of the negative impact
CTEPH has on the pulmonary and
cardiac systems, understanding the
pathophysiology behind the disease
process is a clinically relevant and
significant to the profession of Nurse
Anesthetists.

Treatment
Pulmonary Thromboendarterectomy
•

•

•
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“Pulmonary thromboendarterectomy (PTE) is a surgical
procedure that removes the obstructing thromboembolic
material, resulting in significant improvement and, in
many cases, the normalization of pulmonary artery
pressure and right ventricular function, and thus
improved survival and quality of life as compared with
inoperable patients” (Kamenskaya et al., 2017, pp. 747–
748)
PTE is the most effective treatment for CTEPH with
mortality rates reduced from 20% to <5% in experienced
centers (Stanzel et al., 2018)
Reperfusion injury is the most common injury and cause
of morbidity and mortality, occurring in 10-40% of PTE
patients postoperatively (Buchart et al., 2019).
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Nursing Implications
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Figrue 1: Determinants of the resolution or persistence of chronic thromboemboli disease
after acute pulmonary embolism (PE). After acute PE, there are clinical risk factors
(including the size of the thrombus and presence of right ventricular [RV] strain), mediators
of thrombus remodeling (i.e., IL-8, transforming growth factor [TGF]-b), inflammatory
mediators, and defects in fibrinolysis that combine to determine whether the thrombotic
material resolves or becomes a collagen-rich vascular scar. About 30% of patients will have
persistent defects after acute PE (represented in red), and a minority of these patients
develop chronic thromboembolic pulmonary hypertension (Fernandes et al., 2016, p. 209).

•

Figure 3 Chest radiograph of a 40-year-old female with chronic thromboembolic
pulmonary hypertension. There is mild cardiomegaly with asymmetric
enlargement of the proximal pulmonary arteries (star). Note the multifocal
atelectatic bands (thing arrows) in the right lung and a cavitating infarct (thick
arrows) in the left lung (Gopalan et al., 2016, p. 223).
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Management of CTEPH patients presents many clinical
complications for anesthesia providers as it impairs both
respiratory and cardiac systems, so it is imperative that
anesthesia providers “are well equipped to manage
patients for surgeries with their potential complications”
(Chen et al., 2019, p. 169).

